Xenon Pharmaceuticals Inc. (XENE)
NASDAQ
Xenon Pharmaceuticals Inc. Operating Income 2012–2025
Xenon Pharmaceuticals Inc. annual/quarterly operating income history and growth rate from 2012 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Xenon Pharmaceuticals Inc. operating income for the quarter ending March 31, 2026 was -112.3 M, a 54.43% increase year-over-year.
- Xenon Pharmaceuticals Inc. operating income for the twelve months ending March 31, 2026 was -375.6 M, a 56.55% increase year-over-year.
- Xenon Pharmaceuticals Inc. annual operating income for 2025 was -373.1 M, a 33.57% increase from 2024.
- Xenon Pharmaceuticals Inc. annual operating income for 2024 was -279.3 M, a 30.48% increase from 2023.
- Xenon Pharmaceuticals Inc. annual operating income for 2023 was -214.1 M, a 65.75% increase from 2022.
- Xenon Pharmaceuticals Inc. annual operating income for 2022 was -129.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Xenon Pharmaceuticals Inc. Operating Income — FAQ
Xenon Pharmaceuticals Inc. (XENE) operating income over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
What is Xenon Pharmaceuticals Inc.'s operating income?
Xenon Pharmaceuticals Inc. (XENE) reported operating income of -$373M for fiscal 2025.
Where can I see XENE's operating income history?
The chart and table above show Xenon Pharmaceuticals Inc.'s operating income by year and by quarter, including the growth rate.